No abstract

No abstract

r. wanek, abby bauer, and heather r. bream-rouwenhorst Am J Health-Syst Pharm. 2013; 70:1716-23

No abstract

No abstract

Background:There is a variety of treatment options for patients with transplant-ineligible relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL). One established option is the chemotherapy-based regimen of rituximab, gemcitabine, and oxaliplatin (R-GemOx). Since 2018, the European Medicines Agency has approved several novel targeted therapies for this indication, including CAR T therapies axicabtagene ciloleucel (axi-cel), lisocabtagene maraleucel (liso-cel), and tisagenlecleucel (tisa-cel), as well as the antibody-drug conjugate polatuzumab vedotin alongside bendamustine and rituximab (pola-BR) and the anti-CD19 monoclonal antibody tafasitamab in combination with lenalidomide (Tafa-L). Despite promising impacts on clinical outcomes, these interventions are associated with high treatment costs. The resulting economic burden necessitates the performance of costeffectiveness analyses (CEAs). In Germany, efficiency frontiers (EF) are the recommended approach to conduct CEAs within one indication area.